Emergent BioSolutions Investors With Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) to determine whether the Company engaged in securities fraud or other unlawful business practices.
On April 19, 2021, a class action lawsuit was filed in United States District Court for the District Of Maryland on behalf of Emergent investors who purchased, or otherwise acquired, Emergent’s common stock between July 6, 2020 and March 31, 2021, both dates inclusive (the “Class Period”).
INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, EMERGENT’S COMMON STOCK DURING THE CLASS PERIOD AND SUFFERED LOSSES GREATER THAN $100,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT KEVIN CAULEY, DIRECTOR, CLIENT RELATIONS, (215) 792-6676, EXT. 802, [email protected], [email protected], [email protected], TO DISCUSS THE SECURITIES CLASS ACTION INVESTIGATION OR POTENTIAL LEGAL CLAIMS.